| 那他珠单抗注射液 |
| |
| 引用本文： | 孙忠实,朱珠. 那他珠单抗注射液[J]. 中国新药杂志, 2006, 15(19): 1694-1696 |
| |
| 作者姓名： | 孙忠实 朱珠 |
| |
| 作者单位： | 1. 海军总医院,北京,100037
2. 中国医学科学院中国协和医科大学北京协和医院药剂科,北京,100730 |
| |
| 摘 要： | 那他珠单抗注射液（natalizumab injection），是由Biogen Idec与Elan制药公司联合研发的一种重组人源化IgG4k单克隆抗体，商品名为Tysabri。美国FDA已批准其用于治疗多发性硬化症（multiple sclerosis，MS）。现对其药理特性、临床评价以及应用前景做一综述。
|
| 关 键 词： | 那他珠单抗注射液 多发性硬化症 进行性多灶性脑白质病 |
| 文章编号： | 1003-3734（2006）19-1694-03 |
| 收稿时间： | 2006-01-25 |
| 修稿时间： | 2006-01-25 |
Natalizumab for injection |
| |
| SUN Zhong-shi,ZHU Zhu. Natalizumab for injection[J]. Chinese Journal of New Drugs, 2006, 15(19): 1694-1696 |
| |
| Authors: | SUN Zhong-shi ZHU Zhu |
| |
| Affiliation: | 1 The Navy Hospital, Beijing 100037, China ; 2 Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China |
| |
| Abstract: | Natalizumab, as a monoclonal antibody, copies how the body's immune system deals with pathogens, but instead, it is attaching to alpha-4-integrin on the body's lymphocytes rather than to a pathogen. It was being marketed under the brand name Tysabri by Elan and Biogen. FDA approved it to treat multiple sclerosis in 2004. However, FDA was issuing a public health advisory to inform patients and health care providers about the suspended marketing of Tysabri (natalizumab) due to two serious adverse events reported with its use in 2005. This paper summarized the pharmacology, mechanism and clinical applications of natalizumab. |
| |
| Keywords: | natalizumab for injection multiple sclerosis progressive muhifocal leukoencephalopathy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
